Morphine intranasal - Adhera Therapeutics
Latest Information Update: 31 Dec 2021
At a glance
- Originator Nastech Pharmaceutical Company
- Developer Marina Biotech
- Class Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer pain; Dental pain; Pain
Most Recent Events
- 25 Aug 2010 Marina Biotech is seeking to divest its nasal drug delivery programme
- 01 Apr 2010 MDRNA acquires Cequent Pharmaceuticals and is renamed Marina Biotech
- 01 Jun 2006 Phase-II clinical trials in Cancer pain in USA (Intranasal)